Erlotinib/gemcitabine

Erlotinib/gemcitabine Reactions 1680, p131 - 2 Dec 2017 Interstitial lung disease: 2 case reports In the POLARIS (Post-Launch All-patient- Registration Surveillance) study for safety investigation of gemcitabine and erlotinib, 2 patients were described [ages and sexes not stated], who developed interstitial lung disease (ILD) following treatment with gemcitabine [route not stated] and erlotinib [duration of treatment to reactions onsets not stated] for pancreatic cancer. Case 1: The patient, who had pancreatic cancer, started receiving treatment with gemcitabine 1000 mg/m weekly for 3 weeks, followed by a 1-week rest and oral erlotinib 100mg once daily. However, following gemcitabine and erlotinib administration, the patient developed ILD, which was considered to be treatment related. Eventually, the ILD had recovered, but the patient experienced a sequela. Case 2: The patient, who had pancreatic cancer, started receiving treatment with gemcitabine 1000 mg/m2 weekly for 3 weeks, followed by a 1-week rest and oral erlotinib 100mg once daily. However, following gemcitabine and erlotinib administration, the patient developed ILD, which was considered to be treatment related [outcome not stated]. Author comment: "Outcomes of ILD events were . . . 1 patient (1.9%) had a sequela and the outcome was unknown for 1 patient (1.9%)." "After reviewing the POLARIS data, the ILD review committee recommended that patients with pancreatic cancer should be evaluated for the risk factors identified here prior to beginning GE treatment. During GE treatment. . .If ILD symptoms occur, discontinuation of GE is recommended." Furuse J, et al. Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis. Japanese Journal of Clinical Oncology 47: 832-839, No. 9, 24 May 2017. Available from: URL: http:// doi.org/10.1093/jjco/hyx075 - Japan 803284325 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Erlotinib/gemcitabine

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/erlotinib-gemcitabine-40jeFYiqsl
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39062-5
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p131 - 2 Dec 2017 Interstitial lung disease: 2 case reports In the POLARIS (Post-Launch All-patient- Registration Surveillance) study for safety investigation of gemcitabine and erlotinib, 2 patients were described [ages and sexes not stated], who developed interstitial lung disease (ILD) following treatment with gemcitabine [route not stated] and erlotinib [duration of treatment to reactions onsets not stated] for pancreatic cancer. Case 1: The patient, who had pancreatic cancer, started receiving treatment with gemcitabine 1000 mg/m weekly for 3 weeks, followed by a 1-week rest and oral erlotinib 100mg once daily. However, following gemcitabine and erlotinib administration, the patient developed ILD, which was considered to be treatment related. Eventually, the ILD had recovered, but the patient experienced a sequela. Case 2: The patient, who had pancreatic cancer, started receiving treatment with gemcitabine 1000 mg/m2 weekly for 3 weeks, followed by a 1-week rest and oral erlotinib 100mg once daily. However, following gemcitabine and erlotinib administration, the patient developed ILD, which was considered to be treatment related [outcome not stated]. Author comment: "Outcomes of ILD events were . . . 1 patient (1.9%) had a sequela and the outcome was unknown for 1 patient (1.9%)." "After reviewing the POLARIS data, the ILD review committee recommended that patients with pancreatic cancer should be evaluated for the risk factors identified here prior to beginning GE treatment. During GE treatment. . .If ILD symptoms occur, discontinuation of GE is recommended." Furuse J, et al. Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis. Japanese Journal of Clinical Oncology 47: 832-839, No. 9, 24 May 2017. Available from: URL: http:// doi.org/10.1093/jjco/hyx075 - Japan 803284325 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve Freelancer

DeepDyve Pro

Price
FREE
$49/month

$360/year
Save searches from Google Scholar, PubMed
Create lists to organize your research
Export lists, citations
Read DeepDyve articles
Abstract access only
Unlimited access to over
18 million full-text articles
Print
20 pages/month
PDF Discount
20% off